» Articles » PMID: 35341051

A Comparative Study of the Capability of MSCs Isolated from Different Human Tissue Sources to Differentiate into Neuronal Stem Cells and Dopaminergic-like Cells

Overview
Journal PeerJ
Date 2022 Mar 28
PMID 35341051
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neurodegenerative diseases are characterized by progressive neuronal loss and degeneration. The regeneration of neurons is minimal and neurogenesis is limited only to specific parts of the brain. Several clinical trials have been conducted using Mesenchymal Stem Cells (MSCs) from different sources to establish their safety and efficacy for the treatment of several neurological disorders such as Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.

Aim: The aim of this study was to provide a comparative view of the capabilities of MSCs, isolated from different human tissue sources to differentiate into neuronal stem cell-like cells (NSCs) and possibly into dopaminergic neural- like cells.

Methods: Mesenchymal stem cells were isolated from human bone marrow, adipose, and Wharton's jelly (WJ) tissue samples. Cells were characterized by flow cytometry for their ability to express the most common MSC markers. The differentiation potential was also assessed by differentiating them into osteogenic and adipogenic cell lineages. To evaluate the capacity of these cells to differentiate towards the neural stem cell-like lineage, cells were cultured in media containing small molecules. Cells were utilized for gene expression and immunofluorescence analysis at different time points.

Results: Our results indicate that we have successfully isolated MSCs from bone marrow, adipose tissue, and Wharton's jelly. WJ-MSCs showed a slightly higher proliferation rate after 72 hours compared to BM and AT derived MSCs. Gene expression of early neural stem cell markers revealed that WJ-MSCs had higher expression of Nestin and PAX6 compared to BM and AT-MSCs, in addition to LMX expression as an early dopaminergic neural marker. Immunofluorescence analysis also revealed that these cells successfully expressed SOX1, SOX2, Nestin, TUJ1, FOXA2 and TH.

Conclusion: These results indicate that the protocol utilized has successfully differentiated BM, AT and WJ-MSCs into NSC-like cells. WJ-MSCs possess a higher potential to transdifferentiate into NSC and dopaminergic-like cells. Thus, it might indicate that this protocol can be used to induce MSC into neuronal lineage, which provides an additional or alternative source of cells to be used in the neurological cell-based therapies.

Citing Articles

The role of MicroRNAs in mesenchymal stem cell differentiation into vascular smooth muscle cells.

Abolhasani S, Ahmadi Y, Rostami Y, Fattahi D Cell Div. 2025; 20(1):6.

PMID: 40055797 PMC: 11887104. DOI: 10.1186/s13008-025-00146-0.


Unraveling the Exosome-miR-133a Axis: Targeting TGF-β Signaling via WJ-MSC-Derived Exosomes for Anti-Fibrotic Therapy in Liver Fibrosis.

Saki S, Monjezi S, Ghaffari F, Orak G, Salehipour Bavarsad S, Khedri A Iran Biomed J. 2024; 28(5 & 6):235-44.

PMID: 39629623 PMC: 11829155. DOI: 10.61186/ibj.4357.


Effect of cigarette smoke on the proliferation, viability, gene expression, and cellular functions of adipose-derived mesenchymal stem cells from smoking and non-smoking donors.

Salah B, Shahin D, Sarhan M, Al-Karmi J, Al-Kurdi B, Al-Atoom R Biol Open. 2024; 13(12).

PMID: 39625294 PMC: 11646114. DOI: 10.1242/bio.061665.


Effect of hypoxia on proliferation and differentiation of induced pluripotent stem cell-derived mesenchymal stem cells.

Alwohoush E, Ismail M, Al-Kurdi B, Barham R, Al Hadidi S, Awidi A Heliyon. 2024; 10(19):e38857.

PMID: 39421364 PMC: 11483329. DOI: 10.1016/j.heliyon.2024.e38857.


Cutting-edge regenerative therapy for Hirschsprung disease and its allied disorders.

Yoshimaru K, Matsuura T, Uchida Y, Sonoda S, Maeda S, Kajihara K Surg Today. 2023; 54(9):977-994.

PMID: 37668735 DOI: 10.1007/s00595-023-02741-6.


References
1.
Wattanapanitch M, Klincumhom N, Potirat P, Amornpisutt R, Lorthongpanich C, U-Pratya Y . Dual small-molecule targeting of SMAD signaling stimulates human induced pluripotent stem cells toward neural lineages. PLoS One. 2014; 9(9):e106952. PMC: 4160199. DOI: 10.1371/journal.pone.0106952. View

2.
Musial-Wysocka A, Kot M, Majka M . The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019; 28(7):801-812. PMC: 6719501. DOI: 10.1177/0963689719837897. View

3.
Fu M, Li C, Lin H, Chen P, Calkins M, Chang Y . Stem cell transplantation therapy in Parkinson's disease. Springerplus. 2015; 4:597. PMC: 4628010. DOI: 10.1186/s40064-015-1400-1. View

4.
Ranjbaran H, Abediankenari S, Mohammadi M, Jafari N, Khalilian A, Rahmani Z . Wharton's Jelly Derived-Mesenchymal Stem Cells: Isolation and Characterization. Acta Med Iran. 2018; 56(1):28-33. View

5.
Aliborzi G, Vahdati A, Mehrabani D, Hosseini S, Tamadon A . Isolation, Characterization and Growth Kinetic Comparison of Bone Marrow and Adipose Tissue Mesenchymal Stem Cells of Guinea Pig. Int J Stem Cells. 2016; 9(1):115-23. PMC: 4961111. DOI: 10.15283/ijsc.2016.9.1.115. View